tbuckley/cabot-search huggingface dataset:
PTU-099 A novel functional bioassay predicts 90-day survival in patients with severe alcoholic hepatitis
Authors: E Yates, M Cramp, A Dhanda
Journal: Gut (2017)

Introduction  Severe alcoholic hepatitis (SAH) has a high mortality and only corticosteroids have a proven short term benefit. Early prediction of treatment response would allow selection of appropriate patients who would benefit from corticosteroids. We have previously reported that a functional bioassay measuring in vitro corticosteroid sensitivity, DILPA, accurately predicts 6 month survival in patients with SAH1. However, due to its requirement for radiation it lacked clinical translatability and a second generation assay, bromodeoxyuridine (BrdU) incorporation in lymphocyte steroid sensitivity assay (BLISS) assay, has been developed and validated in healthy controls2. In this study we aimed to generate preliminary data to determine whether the BLISS assay can be used to predict clinical outcome in patients with SAH.  Method  Peripheral blood was drawn from patients with a clinical diagnosis of SAH (discriminant function [DF] >32). All participants gave informed consent and ethical approval was obtained from the NHS Health Research Authority. All patients were treated with corticosteroids for 28 days. The primary outcome measure was 90 day survival. Peripheral blood mononuclear cells, isolated by density gradient centrifugation, were stimulated with lymphocyte mitogen in the absence or presence of dexamethasone and cultured for 48 hours per previously described protocol2. Proliferation was determined by measuring BrdU incorporation using a commercial kit. The maximum suppression of proliferation by corticosteroids (Imax) was determined.  Results  10 patients were recruited (7 female, median age 50) with mean DF 75. 6 patients survived to 90 days and had a significantly higher Imax than non-survivors (27% v −12%; p=0.01) with clear separation between groups (figure 1). Survivors also had lower Lille score than non-survivors (0.20 v 0.79; p=0.02) but in applying the established threshold of 0.45, 1 patient was misclassified as a steroid non-responder. However, Imax did not correlate with Lille score (r2=0.21) or percentage change in bilirubin from day 0 to day 7 (r2=0.10).  Conclusion  The BLISS assay clearly differentiates survivors from non-survivors at 90 days and shows potential for use as a stratification tool in the initial management of patients with SAH. Further validation in a larger multicentre cohort is planned.  References  . Dhanda, di Mambro, Hunt, McCune, Dayan, Dick, Lee, Collins. Long-term outcome in patients with severe alcoholic hepatitis can be reliably determined using an in vitro measure of steroid sensitivity. Hepatology2015; 61: 1099  . Williams, Stimpson, Collins, Enki, Sinha Lee, Dhanda. Development and validation of a novel bioassay to determine glucocorticoid sensitivity. Biomarker Research 2016; 4: 26  Disclosure of Interest  None Declared
Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy
Authors: Shanshan Jiang, Charles G. Eberhart, Michael Lim, Hye-Young Heo, Yi Zhang, Lindsay Blair, Zhibo Wen, Matthias Holdhoff, Doris Lin, Peng Huang, Huamin Qin, Alfredo Quinones-Hinojosa, Jon D. Weingart, Peter B. Barker, Martin G. Pomper, John Laterra, Peter C.M. van Zijl, Jaishri O. Blakeley, Jinyuan Zhou
Journal: Clinical Cancer Research (2018)

Abstract Purpose: To quantify the accuracy of amide proton transfer-weighted (APTw) MRI for identifying active glioma after treatment via radiographically guided stereotactic tissue validation. Experimental Design: Twenty-one patients who were referred for surgery for MRI features concerning for tumor progression versus treatment effect underwent preoperative APTw imaging. Stereotactic biopsy samples were taken from regions of interest with varying APTw signal intensities. The relationship between final clinical pathology and the histopathology of each of the 64 specimens was analyzed relative to APTw results. Analysis of confirmed recurrent tumor or treatment effect tissue was used to perform ROC analysis. Results: Eighteen of 21 patients had recurrent tumor, and 3 had treatment effect on clinical pathology. In 12 patients, there were multiple histopathologic assignments confirmed within the same tumor. Of the 64 total specimens, 20 specimens were active glioma, 27 mixed active and quiescent glioma, and 17 quiescent/no identifiable tumor. APTw signal intensity and histopathologic assignment, cellularity, and proliferation index had significant positive correlations (R = 0.651, 0.580, and 0.458, respectively; all P &amp;lt; 0.001). ROC analysis with a 1.79% APTw intensity cutoff differentiated active from nonactive tumor (AUC of 0.881) with 85.1% sensitivity and 94.1% specificity. Analysis of clinical pathology showed the mean APTw intensity for each patient had 94.4% sensitivity and 100% positive predictive value for identifying recurrent glioma at this cutoff. Conclusions: APTw imaging hyperintensity may be a marker of active malignant glioma. It is able to distinguish between regions of heterogeneous abnormality on anatomic brain MRI with high sensitivity and specificity.
P2.03-01 Prevalence of EGFR Alterations in Chilean Lung Cancer Patients: A Retrospective Study
Authors: R. Gejman, M.L. Bravo, M. Muñoz, I. Retamal, B. Nervi, C. Sanchez, C. Ibañez, J. Peña, J. Madrid, J. Briones, P. Perez, M. Garrido, M. Pinto, H. Galindo
Journal: Journal of Thoracic Oncology (2018)
Opioid-induced constipation in patients with cancer pain in Japan: Prospective observational study using Rome IV OIC diagnostic criteria (OIC-J Study)
Authors: H. Imai, S. Fumita, T. Harada, T. Noriyuki, M. Gamoh, Y. Akashi, H. Sato, Y. Kizawa, A. Tokoro
Journal: Annals of Oncology (2018)
MA02.08 The Effect of Nabilone on Appetite, Nutritional Status, and Quality of Life in Lung Cancer Patients: A Randomized, Double-Blind Clinical Trial
Authors: J. Turcott, M.D.R. Guillen- Núñez, D. Flores, L. Oñate, Z. Zatarain-Barrón, F. Barrón, O. Arrieta
Journal: Journal of Thoracic Oncology (2018)
MA26.09 Lazertinib, a Third Generation EGFR-TKI, in Patients with EGFR-TKI-Resistant NSCLC: Updated Results of a Phase I/II Study
Authors: B.C. Cho, J. Han, S. Kim, K. Lee, D. Kim, Y. Lee, G. Lee, J. Lee, E.K. Cho, J. Kim, S.S. Lee, Y.J. Min, J. Kim, S.W. Shin, H.R. Kim, M.H. Hong, J.S. Ahn, S. Kang, S. Kim, S.B. Jang, S. Choi, M. Ahn
Journal: Journal of Thoracic Oncology (2018)
Surgeon is struck off after tribunal says that sanctions would not work
Authors: Clare Dyer
Journal: BMJ (2018)

A medical practitioners tribunal has taken the unusual step of striking a doctor off the UK medical register for deficient professional performance, saying that the surgeon’s “complete lack of insight” made sanctions of imposed working conditions or suspension both inadequate and unworkable. In the past five years only 12 doctors have been struck off for deficient performance alone.

Colleagues became concerned about Thomas Biesgen’s work during brief stints in 2012 at Addenbrooke’s Hospital in Cambridge, where he was a microsurgical fellow, and at Leeds Teaching Hospital NHS Trust, where he was seconded as a locum consultant in plastic surgery.

A letter to the General Medical Council (GMC) from the executive medical director at Cambridge University …
P2.17-11 Impact of Quantitatively Assessed Emphysema on Chest Tube Drainage After Lobectomy for Non-Small Cell Lung Cancer
Authors: T. Gil, Z. Grochowski, J. Warmus, K. Bederski, P. Kocoń, J. Włodarczyk, Ł. Trybalski, T. Smęder, K. Żanowska, P. Hajder, B. Kołodziejczyk, W. Cieślak, J. Kużdżał, R. Banyś
Journal: Journal of Thoracic Oncology (2018)
P1.03-24 TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC
Authors: F. Expósito, M. Villalba, M.J. Pajares, M. Redrado, C. Sainz, I. Wistuba, C. Behrens, E. Redin, C. Andrea, C. Cirauquiz, L. Montuenga, R. Pio, A. Calvo
Journal: Journal of Thoracic Oncology (2018)
The Next Stage of Buprenorphine Care for Opioid Use Disorder
Authors: Stephen A. Martin, Lisa M. Chiodo, Jordon D. Bosse, Amanda Wilson
Journal: Annals of Internal Medicine (2018)

Buprenorphine has been used internationally for the treatment of opioid use disorder (OUD) since the 1990s and has been available in the United States for more than a decade. Initial practice recommendations were intentionally conservative, were based on expert opinion, and were influenced by methadone regulations. Since 2003, the American crisis of OUD has dramatically worsened, and much related empirical research has been undertaken. The findings in several important areas conflict with initial clinical practice that is still prevalent. This article reviews research findings in the following 7 areas: location of buprenorphine induction, combining buprenorphine with a benzodiazepine, relapse during buprenorphine treatment, requirements for counseling, uses of drug testing, use of other substances during buprenorphine treatment, and duration of buprenorphine treatment. For each area, evidence for needed updates and modifications in practice is provided. These modifications will facilitate more successful, evidence-based treatment and care for patients with OUD.
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
Authors: F. André, E.M. Ciruelos, G. Rubovszky, M. Campone, S. Loibl, H.S. Rugo, H. Iwata, P. Conte, I.A. Mayer, B. Kaufman, T. Yamashita, Y.-S. Lu, K. Inoue, M. Takahashi, Z. Pápai, A.-S. Longin, D. Mills, C. Wilke, S. Hirawat, D. Juric
Journal: Annals of Oncology (2018)
Peripheral blood mononuclear cell biomarkers predict response to immune checkpoint inhibitor therapy in metastatic breast cancer
Authors: Y. Yuan, W. Hou, S. Padam, P. Frankel, M.S. Sedrak, J. Portnow, J. Mortimer, C. Yeon, A. Hurria, A. Tang, N. Martinez, P. Lee
Journal: Annals of Oncology (2018)
P1.01-109 Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Authors: H. Zhao, Z. Zhang, S. Li, W. Fang, Y. Ma, Y. Zhang, Y. Yang, F. Luo, Y. Huang, L. Zhang
Journal: Journal of Thoracic Oncology (2018)
MA16.05 MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)
Authors: A. Schrock, D. Pavlick, M. Rosenzweig, R. Erlich, L. Albacker, G. Frampton, J. Ross, V. Miller, S. Ali, S. Ou
Journal: Journal of Thoracic Oncology (2018)
P3.01-97 Which is Better Prognostic Factor, PS, Inflammatory Marker, or PD-L1 Expression in Treating NSCLC with Nivolmab; A Retrospective Analysis
Authors: A. Tamiya, Y. Taniguchi, Y. Inagaki, N. Saijo, Y. Naoki, K. Otsuka, K. Okishio, T. Kasai, S. Atagi
Journal: Journal of Thoracic Oncology (2018)
Long-term safety of crizotinib in previously treated patients (pts) with ALK-positive advanced/metastatic non-small cell lung cancer (NSCLC)
Authors: L. Crinò, M.-J. Ahn, J.-Y. Han, X. Liu, S.-H.I. Ou, A.T. Shaw, P.-C. Yang, Y.-K. Shi, S. Lanzalone, A. Polli, K.D. Wilner, D.-W. Kim
Journal: Annals of Oncology (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Authors: Simon Portsmouth, David van Veenhuyzen, Roger Echols, Mitsuaki Machida, Juan Camilo Arjona Ferreira, Mari Ariyasu, Peter Tenke, Tsutae Den Nagata
Journal: The Lancet Infectious Diseases (2018)
Impaired survival in resected glioblastoma multiforme patients treated with early chemoradiation
Authors: L.P. del Carpio, P. Gomila, S.D. Camacho, S. Moron, M. Riudavets, C. Molto, A. Bujosa, M. Borrell, R. Teres, B. Martin, P. Gallardo, E. Acosta, L. Tilea, A. Soto, C. De Quintana, J. Craven-Bartle, A. Gallardo, B. Gomez, S. Bonilla, O. Gallego
Journal: Annals of Oncology (2018)
Prolonged overall survival for patients with bone-only metastases at presentation of metastatic breast cancer
Authors: E. Curtit, F. Bazan, L. Chaigneau, G. Mouillet, E. Dobi, L. Mansi, N. Meneveau, M.-J. Paillard, G. Meynard, E. Klajer, C. Villanueva, P. Montcuquet, X. Pivot, L. Cals
Journal: Annals of Oncology (2018)
A phase I/II dose escalation study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
Authors: N. Ngamphaiboon, S. Lukerak, C. Jiarpinitnun, A. Jinawath, N. Jinawath, J. Juengsamarn, L. Arsa, J. Konmun, N. Kongsuphon, N. Sankaseam, E. Sirachainan, P. Witoonpanich, A. Kositwattanarerk, P. Pattaranutaporn
Journal: Annals of Oncology (2018)
P3.01-88 Clinical and Molecular Analysis of Long-Term Survivors with Advanced Non-Small Cell Lung Cancer: A Multicenter Experience in Madrid
Authors: M. Sereno Moyano, S. Falagan, J. Moreno Rubio, R. Álvarez Álvarez, M.E. Olmedo, X. Mielgo, F. Navarro, R. Ramos, A.B. Enguita, A. Benito, M. Cebollero, I. Alemany, C. Castillo, E. Casado, S. Ponce Aix
Journal: Journal of Thoracic Oncology (2018)
P2.09-03 Rapid-Immunocytochemistry for Evaluation of Surgical Margin in Sublobar Pulmonary Resection
Authors: N. Kurihara, H. Saito, H. Nanjo, Y. Hiroshima, K. Imai, H. Konno, M. Atari, T. Matsuo, S. Watanabe, H. Iwai, H. Suzuki, Y. Minamiya
Journal: Journal of Thoracic Oncology (2018)
The frequency of primary cilia, CD8+ tumor infiltrating lymphocytes and PD-1 expression in renal cell carcinoma of clear-cell type
Authors: J. Dvorak, B. Rosova, A. Filipova, D. Hadzi Nikolov, L. Dusek, A. Rozsypalova, J. Proks, I. Richter, B. Melichar, T. Buchler, R. Zachoval, R. Matej
Journal: Annals of Oncology (2018)
MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC
Authors: F. Oezkan, K. He, D. Owen, M. Pietrzak, R. Kitzler, R. Pearson, A. Nicholas, P. Bunn, M. Kris, D. Kwiatkowski, B. Johnson, F. Hirsch, I. Wistuba, V. Rusch, J. Lee, M. Gandhi, K. Schulze, D. Shames, G. Lozanski, D. Carbone
Journal: Journal of Thoracic Oncology (2018)
P1.17-05 Accelerated Radiotherapy for Non-Small Cell Lung Cancer: A 12 Year Retrospective Review of Two Dose Fractionation Schedules
Authors: S. Robinson, B. Tahir, K. Absalom, D. Tripathi, P. Fisher, T. Das, C. Lee, E. Bates, M. Hatton
Journal: Journal of Thoracic Oncology (2018)
Association between early immune-related adverse events and clinical outcomes in patients with advanced non-small cell lung cancer treated with pembrolizumab as first-line therapy: A retrospective multicenter cohort study
Authors: K. Hosoya, D. Fujimoto, M. Tamiya, A. Tamiya, H. Suzuki, K. Hirano, T. Yokoyama, M. Morita, Y. Fukuda, M. Kanazu, T. Makio
Journal: Annals of Oncology (2018)
P2.16-18 Study of Interstitial Lung Disease and Acute Exacerbation in Patients Receiving Radiation Therapy for Lung Cancer in Japan
Authors: Y. Hagiwara, Y. Nakayama, T. Kato, Y. Saito, K. Hayakawa, N. Nakamura, Y. Kitamoto, S. Takahashi, K. Tsujino, N. Kubo, Y. Tamaki, M. Kusumoto, T. Iwasawa, Y. Nagata
Journal: Journal of Thoracic Oncology (2018)
OA03.07 Three-Dimensional Immunofluorescence Analysis of Dynamic Vessel Co-Option of Spread Through Air Spaces (STAS) in Lung Cancer
Authors: Y. Yagi, R. Aly, K. Tabata, N. Rekhtman, T. Eguchi, J. Montecalvo, K. Manova, P. Adusumilli, M. Hameed, W. Travis
Journal: Journal of Thoracic Oncology (2018)
Phase I experience with rogaratinib in patients with head and neck cancer selected based on FGFR mRNA overexpression
Authors: M. Joerger, S. Takahashi, C.M. Sayehli, S. Slosarczyk, A. Navarro Mendivil, P.A. Cassier, H. Nogai, C. Zhang, F. Sei, S. Bender, P. Ellinghaus, M. Tahara
Journal: Annals of Oncology (2018)
Abstract 11190: The Prognostic Impact of Lack of Chest Pain in Young Patients With Acute Coronary Syndromes
Authors: Amar M Salam, Khalid F AlHabib, Wael Almahmeed, Alawi Alsheikh-Ali, Kadhim Sulaiman, Haitham Amin, Jawad Al-Lawati, Ahmed Al-Motarreb, Nidal Asaad, Rajvir Singh, Jassim Al Suwaidi
Journal: Circulation (2014)

Objectives: Although lack of chest pain on presentation with acute coronary syndromes (ACS) has been associated with poor outcomes; yet there is limited literature examining the outcomes of ACS wit...
P1.01-07 Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
Authors: A. Botticella, T. Ibrahim, L. Mezquita, L. Hendriks, J. Le Pavec, R. Ferrara, C. Caramella, J. Remon, S. Champiat, J. Michot, P. Lavaud, F. Aboubakar Nana, P. Gustin, D. Planchard, A. Gazzah, A. Marabelle, D. Eric, B. Besse, C. Le Pechoux
Journal: Journal of Thoracic Oncology (2018)
P1.01-73 Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience
Authors: E. Capelletto, M.R. Migliorino, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F. Di Costanzo, A. Delmonte, G. Romano, A. Misino, V. Scotti, V. Gregorc, S. Pisconti, G. Ceresoli, A. Del Conte, L. Ciuffreda, I. Colantonio, E. Bria, S. Ricciardi, A. Manzo, G. Metro, A.M. Morelli, R. Critelli, I. Stura, G. Migliaretti, S. Novello
Journal: Journal of Thoracic Oncology (2018)
Brexit: ministers are running out of time to secure drug supplies, industry bosses warn
Authors: Gareth Iacobucci
Journal: BMJ (2018)

Drug industry bosses have warned the government that it is running out of time to negotiate a Brexit deal that will safeguard the supply of medicines when the UK leaves the European Union.

Giving evidence to the House of Commons health select committee on 23 October, Martin Sawer, director of the Healthcare Distribution Association, warned that a no-deal scenario could lead to medicine shortages and price rises and called for emergency powers to reduce the impact on patients.

Mike Thompson, chief executive of the Association of the British Pharmaceutical Industry, …
P2.01-63 Are Heart Doses Associated with Survival in NSCLC Treated with Post-Operative Radiotherapy? A National Population-Based Study
Authors: C.C. Lee, G. Chua, H. Zheng, Y.Y. Soon, L.L. Foo, A. Thiagarajan, S.P. Yap, T.R. Siow, W.L. Ng, K. Chua, C. Yip, B. Chia, Y.Y. Ng, Z. Master, P.W. Tan, Y.I. Tan, Y.F. Leong, J.F.E. Loria, B. Vellayappan, W.Y. Koh, C.N. Leong, J. Tey, I. Tham, K.W. Fong
Journal: Journal of Thoracic Oncology (2018)
P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review
Authors: B. Han, B. Zhang, Y. Zhang, J. Xu, X. Zhang, T. Chu, S. Wang, J. Qian, R. Qiao, J. Lu, L. Zhang
Journal: Journal of Thoracic Oncology (2018)
P2.01-75 Study of Molecular Alterations in Cytological Smears By FISH In Patients with Advanced Non Small Cell Lung Carcinoma (NSCLC).
Authors: J. Pandolfi, J. Urbistondo, M. Labanca, J. Minatta, M. Dalurzo, P. De La Iglesia Niveyro
Journal: Journal of Thoracic Oncology (2018)
P3.04-22 Response of Brain Metastases in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy and Brain Directed Radiotherapy
Authors: D. Akhoundova Sanoyan, M. Hüllner, J. Kraft, L. Bankel, S. Lee, N. Ansratschke, A. Curioni Fontecedro
Journal: Journal of Thoracic Oncology (2018)
First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study
Authors: P. García Alfonso, M. Valladares-Ayerbes, J. Muñoz Luengo, P. Pimentel, J.M. Viéitez, J.J. Cruz Hernandez, M. Llanos, C. Garcia Girón, A. Salud Salvia, A. Lloansí Vila
Journal: Annals of Oncology (2018)
First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study
Authors: J.L. Blum, S.L. McCune, M.A. Salkeni, D.M. Anderson, J.J. Migas, S. Lakhanpal, K. Patel, A. Bardia, G. Rocque, J. Wang, J.C. Cappelleri, G. Comstock, Y. Wang, D. Tripathy
Journal: Annals of Oncology (2018)
Abstract 20699: Reduction of Endothelial Arnt Mediates Vascular Dysfunction in Diabetes
Authors: Maura Knapp, Mei Zheng, Nikola Sladojevic, Qiong Zhao, James K Liao, Rongxue Wu
Journal: Circulation (2016)

Introduction: Endothelial dysfunction, a central hallmark of diabetes, predisposes diabetic patients to a number of cardiovascular complications. We have previously shown that ARNT is a critical re...
Statin use and outcome in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated in the TROPIC trial
Authors: D. Lorente, G.A. De Velasco Oria, J. Carles, S. Gillessen, K. Fizazi, A. Joshua, M. Eisenberger, O. Sartor, J.S. de Bono
Journal: Annals of Oncology (2018)
P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective
Authors: K. Perdrizet, T. Stockley, M. Tsao, J. Morganstein, S. Kamel-Reid, L. Ranich, F. Shepherd, P. Bradbury, G. Liu, D. Hwang, P. Pal, J. Schwock, S. Boerner, A. Sacher, J. Law, N. Leighl
Journal: Journal of Thoracic Oncology (2018)
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial evaluating the PD-L1 probody therapeutic CX-072 in combination with ipilimumab (ipi) in patients (pts) with advanced solid tumors
Authors: R. Plummer, R.E. Sanborn, E.G.E. de Vries, P. Lorusso, H.-T. Arkenau, N. Uboha, J. Wydmanski, M.J. Fidler, V. Boni, J. Garcia-Corbacho, R. Humphrey, M. Will, K.A. Autio, A.B. El-Khoueiry, C.W. Menke-van der Houven van Oordt, F. Thistlethwaite
Journal: Annals of Oncology (2018)
Indicators of non-uptake of breast cancer screening: Results from the EDIFICE 6 survey
Authors: J.-F. Morere, J. Viguier, L. Greillier, M. Roupret, C. Touboul, C. Lhomel, S. Couraud, T. de La Motte Rouge, F. Eisinger
Journal: Annals of Oncology (2018)
P2.01-90 PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small Cell Lung Cancer Patients with or without EGFR Mutation
Authors: T. Siripoon, P. Incharoen, N. Trachu, D. Munthum, K. Kamprerasart, T. Reungwetwattana
Journal: Journal of Thoracic Oncology (2018)
MASTER KEY project: A basket/umbrella trial for rare cancers in Japan
Authors: S. Noda, K. Yonemori, N. Shirakawa, H.S. Okuma, T. Shimizu, A. Hirakawa, T. Shibata, T. Sukigara, N. Okita, A. Kawai, N. Yamamoto, K. Nakamura, H. Mano, T. Nishida, Y. Fujiwara
Journal: Annals of Oncology (2018)
Metastatic colorectal signet-ring cell carcinoma: Clinical, histological and molecular description from an AGEO French multicenter retrospective cohort
Authors: M. Allart-Sava, F. Le Roy, S. Kim, D. Sefrioui, C. Mariette, A. Zaanan, B.J.-C. Rousseau, M. Ben Abdelghani, C. De La Fouchardière, W. Cacheux, R. Legros, S. Louafi, D. Tougeron, N. Fares, G. Roquin, A.L. Bignon Bretagne, M. Maillet, B. Tchoundjeu, A. Pozet, V. Hautefeuille
Journal: Annals of Oncology (2018)
P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
Authors: J. Clarke, V. Stefaniak, M. Batus, K. Winfree, C. Molife, Z. Cui, Y. Han, M. Tawney, P. Bonomi
Journal: Journal of Thoracic Oncology (2018)
P1.03-33 Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population
Authors: C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Y. Chen, M. Fang, G. Chen, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2018)
P1.13-41 In Vitro Evaluation for Optimal MET-TKI Selection in Lung Cancers with MET Mutations Including Exon 14 Skipping
Authors: T. Fujino, K. Suda, Y. Kobayashi, M. Nishino, T. Koga, S. Ohara, M. Chiba, M. Shimoji, T. Takemoto, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2018)